Upcoming EventsMore >>
DateTitle
04/22/14
2:15 p.m. PT
Q1 2014 Amgen Earnings Conference Call
Recent NewsMore >>
DateTitle 
04/17/14Amgen Announces Webcast of 2014 First Quarter Financial Results
THOUSAND OAKS, Calif., April 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:15 p.m. PDT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the... 
Printer Friendly Version
04/04/14Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Results showed that, while the primary end point of durable response rate was met ... 
Printer Friendly Version
03/30/14Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
Data From Two Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented in Late-Breaking Clinical Trials Session at ACC.14 - Data Add to the Three Pivotal Studies Presented Yesterday Positive Results From GAUSS-2 Simultaneously Published in the Journal of the American College of Cardiology Robust Data Presented at ACC.14 From Five Phase 3 Studies in More Than 4,000 Patients Form the Basis of Global Filing Plan THOUSAND OAKS, Calif., March 30, 2014 /PRNewswire/... 
Printer Friendly Version
03/29/14New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol
Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 Positive Results From the Long-Term Safety and Efficacy Study DESCARTES Simultaneously Published in the New England Journal of Medicine and the Monotherapy Study MENDEL-2 Results Simultaneously Published in the Journal of the American College of Cardiology Data From Two Additional Phase 3 Studies on Evolocumab to be Presented in Late-Breaking Session To... 
Printer Friendly Version
What's New
03/30/14
Download Documentation Amgen Investor Meeting, ACC Scientific Session 2014 Presentation
03/27/14
Download Documentation 2013 Annual Report and 10-K
Investor Insights Newsletters
DateTitle
02/11/14
Download Documentation Investor Insights Newsletter - Q4 2013
10/31/13
Download Documentation Investor Insights Newsletter - Q3 2013
08/02/13
Download Documentation Investor Insights Newsletter - Q2 2013
05/08/13
Download Documentation Investor Insights Newsletter - Q1 2013
02/20/13
Download Documentation Investor Insights Newsletter - Q4 2012

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.